In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

(1) Background: Colorectal cancer (CRC) is the third most common cancer and the second
leading cause of cancer-related mortality worldwide. Up to 50% of patients with CRC …

Background In a previous phase 3 trial, treatment with trifluridine–tipiracil (FTD–TPI)
prolonged overall survival among patients with metastatic colorectal cancer. Preliminary …

Background There is a paucity of effective systemic therapy options for patients with
advanced, chemotherapy-refractory colorectal cancer. We aimed to evaluate the efficacy …

Background Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors
have shown encouraging activity in several tumour types, including colorectal cancer. This …

Colorectal cancer (CRC) is a major health concern with multifactorial pathophysiology
representing intense therapeutic challenges. It is well known that deregulation of …

Oncologists face increasingly complex clinical decision-making processes as new cancer
therapies are approved and treatment guidelines are revised at an unprecedented rate. With …

Certain genetic alterations and right-sided primary tumor location are associated with
resistance to anti-epidermal growth factor (EGFR) treatment in metastatic colorectal cancer …

Background Patients with initially unresectable colorectal cancer liver metastases might
qualify for local treatment with curative intent after reducing the tumour size by induction …

Background Contemporary management of patients with synchronous colorectal cancer and
liver metastases is complex. The aim of this project was to provide a practical framework for …